Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1
- PMID: 8064227
- PMCID: PMC2191655
- DOI: 10.1084/jem.180.3.1087
Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1
Abstract
Immunoglobulin G (IgG) molecules are glycosylated in CH2 at Asn297; the N-linked carbohydrates attached there have been shown to contribute to antibody (Ab) stability and various effector functions. The carbohydrate attached to the IgG constant region is a complex biantennary structure. Alterations in the structure of oligosaccharide have been associated with human diseases such as rheumatoid arthritis and osteoarthritis. To study the effects of altered carbohydrate structure on Ab effector function, we have used gene transfection techniques to produce mouse-human chimeric IgG1 Abs in the Chinese hamster ovary (CHO) cell line Lec 1, which is incapable of processing the high-mannose intermediate through the terminal glycosylation steps. We also produced IgG1 Abs in Pro-5, the wild-type CHO cell line that is the parent of Lec 1. The Pro-5-produced Ab (IgG1-Pro-5) was similar to IgG1-My 1, a myeloma-produced IgG1 Ab of the same specificity, in its biologic properties such as serum half-life, ability to effect complement-mediated cytolysis, and affinity for Fc gamma RI. Although the Lec 1-produced Ab, IgG1-Lec 1, was properly assembled and retained antigen specificity, it was incapable of complement-mediated hemolysis and was substantially deficient in complement consumption, C1q binding, and C1 activation. IgG1-Lec 1 also showed reduced but significant affinity for Fc gamma R1 receptors. The in vivo half-life of IgG1-Lec 1 was shorter than that of either the myeloma- or Pro-5-produced counterpart, with more being cleared during the alpha-phase and with more rapid clearance during the beta-phase. Clearance of IgG1-Lec 1 could be inhibited by the administration of yeast-derived mannan. Thus the uptake of IgG1-Lec 1 appears to be accelerated by the presence of terminally mannosylated oligosaccharide. Therefore, certain Ab functions as well as the in vivo fate of the protein are dramatically affected by altered carbohydrate structure. Expression of Igs in cell lines with defined glycosylation mutations is shown to be a useful technique for investigating the contribution of carbohydrate structure to Ab function.
Similar articles
-
Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells.J Immunol. 1998 Apr 1;160(7):3393-402. J Immunol. 1998. PMID: 9531299
-
In vivo trafficking and catabolism of IgG1 antibodies with Fc associated carbohydrates of differing structure.Glycobiology. 2000 Dec;10(12):1347-55. doi: 10.1093/glycob/10.12.1347. Glycobiology. 2000. PMID: 11159927
-
Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region.J Immunol. 1989 Oct 15;143(8):2595-601. J Immunol. 1989. PMID: 2507634
-
IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation.Immunol Rev. 1998 Jun;163:59-76. doi: 10.1111/j.1600-065x.1998.tb01188.x. Immunol Rev. 1998. PMID: 9700502 Review.
-
The role of carbohydrate in the assembly and function of polymeric IgG.Mol Immunol. 2000 Dec;37(18):1081-90. doi: 10.1016/s0161-5890(01)00024-4. Mol Immunol. 2000. PMID: 11451414 Review.
Cited by
-
Key Physicochemical Characteristics Influencing ADME Properties of Therapeutic Proteins.Adv Exp Med Biol. 2019;1148:115-129. doi: 10.1007/978-981-13-7709-9_6. Adv Exp Med Biol. 2019. PMID: 31482497 Review.
-
Assessing monoclonal antibody product quality attribute criticality through clinical studies.MAbs. 2010 Sep-Oct;2(5):500-7. doi: 10.4161/mabs.2.5.12897. Epub 2010 Sep 1. MAbs. 2010. PMID: 20671426 Free PMC article. Review.
-
Structure, heterogeneity and developability assessment of therapeutic antibodies.MAbs. 2019 Feb/Mar;11(2):239-264. doi: 10.1080/19420862.2018.1553476. Epub 2018 Dec 17. MAbs. 2019. PMID: 30543482 Free PMC article. Review.
-
Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection.Infect Immun. 2007 Mar;75(3):1424-35. doi: 10.1128/IAI.01161-06. Epub 2007 Jan 12. Infect Immun. 2007. PMID: 17220317 Free PMC article.
-
Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist's Perspective.Antibodies (Basel). 2021 Jul 26;10(3):30. doi: 10.3390/antib10030030. Antibodies (Basel). 2021. PMID: 34449544 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources